Selective Pulmonary Artery Perfusion with carboplatin for the treatment of NSCLC: a phase I trial
- Conditions
- lung cancernon-small cell lung cancer10029107
- Registration Number
- NL-OMON32894
- Lead Sponsor
- cardioth chir
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Stage c3a en c3b NSCLC
Exclusion Criteria
Other stages of NSCLC, age under 18 years old (however, NSCLC has never been described during childhood), patients who are mentally not able to chose whether to be involved in the study or not, pregnancy or lactation, severe comorbidity, uncontrollable infectious disease, Liver/kidney insufficiency; serum creatinine more than 130 µmol/l and urine creatinine clearance less than 60 ml/min, ALAT and ASAT more than 3 times normal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method